Oxidized – LDL
A More Accurate Bio-Marker Test For Detection Of Coronary Artery Disease
Oxidized LDL is the atherogenic form of LDL-cholesterol. It is a plaque-specific lipoprotein, found only in atherosclerotic plaques and not in normal artery walls. The conversion of LDL-cholesterol to oxidized LDL by reactive oxygen species (ROS; free radicals and peroxides) in the vascular endothelium is now widely recognized and accepted as a key biochemical reaction in the initiation and progression of the atherosclerotic disease process. Oxidized LDL is directly involved in all stages of the atherosclerotic disease process from the conversion of monocyte-macrophages into lipid-laden foam cells; from fatty streak formation to plaque formation; from plaque rupture and intra-arterial thrombosis to ischemia. The level of oxidized LDL found in the blood stream as a result of plaque formation feedback can differentiate between individuals with coronary artery disease from individuals who are “healthy” and not at risk, and can do so with a very high degree of accuracy.
The primary purpose of this notebook is to provide peer-reviewed data from leading medical journals that demonstrate that (1) native LDL must be converted to oxidized LDL in order to become atherogenic, (2) that oxidized LDL is the culprit molecule directly involved the development and progression of atheroscerotic plaque, (3) that the oxidized LDL assay based on the monoclonal antibody 4E6 is a more accurate marker for coronary artery disease than time-honored conventional lipid and lipoprotein markers, (4) that oxidized LDL is a prognostic marker for the progression of atherosclerosis and acute coronary events, and (5) that oxidized LDL will become the biomarker of choice for the diagnosis and therapeutic monitoring of coronary artery disease.
The notebook section of peer reviewed articles contains a summary page for each major topic followed by appropriate peer-reviewed article(s)….
National Screening Institute (NSI) has the exclusive world-wide rights to oxidized LDL and malondialdehyde (MDA)-modified LDL antibodies and corresponding technology developed by Professor Paul Holvoet at the University of Leuven, Belgium.
Here is what we have to offer: Antibodies for targets that are superior to existing biomarkers. The only blood test that reflects atherosclerotic disease activity in the arterial wall. Diagnostic accuracy that is superior to lipoprotein particle profiles. Standard specimen collection and handling. Proprietary license arrangement. Patent protection. A high market potential.
Test kits are available for clinical use. NSI tests kits are manufactured and distributed by Mercodia AB located in Uppsala, Sweden. About 400,000 patients have been evaluated by pharmaceutical companies and research organizations using Mercodia’s sandwich and competitive microtiterplate assays. While the pharmaceutical studies are confidential, some 400 articles/posters have been published.
Clinical use by physicians: Shiel Medical Laboratory runs the oxidized LDL assay on an automated microtiter system and provides 24 hour turn around for physicians in New York. It should be noted that mail-in tests do not require special specimen handling. Future information is available at www.Shiel.com.